# An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Study · id `cardio:ct-nct03514641` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03514641](<https://clinicaltrials.gov/study/NCT03514641>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03514641

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 673 participants.

## Technical summary

Registry record NCT03514641. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-18 (actual); primary completion 2018-11-30 (actual). Results posted on 2021-09-21.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 673 participants (enrolled count; ClinicalTrials.gov record NCT03514641, source copy `cardio:ctgov-nct03514641-2021-09-21`, retrieved 2026-10-26)
- Started: 2017-10-18 (actual) (ClinicalTrials.gov record NCT03514641, source copy `cardio:ctgov-nct03514641-2021-09-21`, retrieved 2026-10-26)
- Primary completion: 2018-11-30 (actual) (ClinicalTrials.gov record NCT03514641, source copy `cardio:ctgov-nct03514641-2021-09-21`, retrieved 2026-10-26)
- Completion: 2018-11-30 (actual) (ClinicalTrials.gov record NCT03514641, source copy `cardio:ctgov-nct03514641-2021-09-21`, retrieved 2026-10-26)
- Results first posted: 2021-09-21 (ClinicalTrials.gov record NCT03514641, source copy `cardio:ctgov-nct03514641-2021-09-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03514641, source copy `cardio:ctgov-nct03514641-2021-09-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03514641-2021-09-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Bexagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Theracos
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Theracos (`cardio:org-theracos`)

## Provenance

Content hash: fbe18c88f398f69e2019c36a00ee381a8bb6ba8e12953ed95b38d96a7877645a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
